MUMBAI, India, Sept. 12 -- Intellectual Property India has published a patent application (202411012808 A) filed by National Institute Of Pharmaceutical Education And Research, Mohali, Punjab, on Feb. 22, 2024, for 'polyvalent tumour necrosis factor - alpha blocking domain antibodies (pvtbdabs) and method of generation thereof.'
Inventor(s) include Abhay Hariram Pande; Suraj Hanumant Shinde; and Sandeep.
The application for the patent was published on Sept. 12, under issue no. 37/2025.
According to the abstract released by the Intellectual Property India: "The present disclosure relates to polyvalent antibodies capable of binding to and inhibiting the activity of tumor necrosis factor alpha (TNF-a). In one aspect, the present disclosure provides novel polyvalent TNF-a blocking domain antibody (PvTBDAbs), capable of binding to human TNF-a with high affinity. In another aspect, the present disclosure provides novel polynucleotide sequences encoding for PvTBDAbs. In another aspect, the present disclosure provides a method to product these PvTBDAbs. The polyvalent antibodies disclosed in this invention can be used to treat a variety of inflammatory and other diseases."
Disclaimer: Curated by HT Syndication.
